Browsing Tag
Medtronic
26 posts
Anteris Technologies (ASX: AVR) stock up 9.6% as PARADIGM trial reaches first US patient enrolments
Edwards and Medtronic own TAVR. Anteris (ASX: AVR) wants in with DurAVR. First US PARADIGM patients enrolled, US$320m raised, and Medtronic is now a shareholder.
Why the $11.5bn global sutures market is splitting into two growth stories
Sutures look like a mature commodity. Antimicrobial coatings, ambulatory surgery and Asia-Pacific demand are quietly turning it into a margin contest.
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.
Can Nia’s 60-channel brain implant redefine closed-loop neuromodulation in memory therapy?
Nia Therapeutics validates its wireless brain implant for closed-loop memory stimulation. Find out how it could transform treatment for traumatic brain injury.
From Medtronic to the market: What MiniMed’s IPO means for CGM and insulin pump competition
Medtronic files IPO for MiniMed, its diabetes device business. Find out what this spin-off could mean for the future of CGM and insulin delivery tech.
Anteris Technologies launches its pivotal trial phase for DurAVR THV, marking a regulatory turning point
Anteris Technologies launches the global PARADIGM pivotal trial of its DurAVR THV, challenging Edwards and Medtronic with biomimetic valve durability data—see how the race unfolds.
Johnson & Johnson to spin off DePuy Synthes, creating the world’s largest standalone orthopaedics company
Find out how Johnson & Johnson’s DePuy Synthes spin-off reshapes the $9 billion orthopaedics market and accelerates the company’s innovation focus.
Medtronic (NYSE: MDT) launches Embrace Gynecology study — will Hugo RAS redefine robotic hysterectomies in the U.S.?
Medtronic’s Embrace Gynecology trial tests Hugo RAS in hysterectomies—can it challenge da Vinci’s dominance and reshape women’s robotic surgery?
Is neuromodulation entering its next growth cycle? Lessons from Medtronic, Axonics, and Boston Scientific
Neuromodulation is moving into its next growth cycle. Explore how Medtronic, Boston Scientific, and Axonics are reshaping bladder control and chronic care.
From stigma to scale: How bladder control therapies are evolving from hidden struggle to healthcare priority
Bladder control therapies are moving from stigma to mainstream care. Discover how rising awareness and innovation are reshaping treatment options globally.